Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. - Wikidata - wikimedia - TriplyDB

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

http://www.wikidata.org/entity/Q36742629

about

First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma Therapeutic Implications of Targeting AKT Signaling in Melanoma PI3K inhibitors as new cancer therapeutics: implications for clinical trial design p38 MAPK and PI3K/AKT Signalling Cascades inParkinson's Disease Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer Autophagy and cancer mTOR kinase inhibitors as potential cancer therapeutic drugs β-caryophyllene and β-caryophyllene oxide-natural compounds of anticancer and analgesic properties Akt activation is responsible for enhanced migratory and invasive behavior of arsenic-transformed human bronchial epithelial cells Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities Choline plasmalogens isolated from swine liver inhibit hepatoma cell proliferation associated with caveolin-1/Akt signaling Oxidative Stress Mediates the Antiproliferative Effects of Nelfinavir in Breast Cancer Cells Trisubstituted-Imidazoles Induce Apoptosis in Human Breast Cancer Cells by Targeting the Oncogenic PI3K/Akt/mTOR Signaling Pathway Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy Single prolonged stress enhances hippocampal glucocorticoid receptor and phosphorylated protein kinase B levels Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.RFP-mediated ubiquitination of PTEN modulates its effect on AKT activation A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets.Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells.Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway.Enhancing mTOR-targeted cancer therapy.Growth and stress response mechanisms underlying post-feeding regenerative organ growth in the Burmese python.RSK promotes G2/M transition through activating phosphorylation of Cdc25A and Cdc25B Cord blood stem cell-mediated induction of apoptosis in glioma downregulates X-linked inhibitor of apoptosis protein (XIAP).Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by suppressing the PI3K/AKT signaling pathway.Time-Based Switching Control of Genetic Regulatory Networks: Toward Sequential Drug Intake for Cancer Therapy.Advanced malignant melanoma: immunologic and multimodal therapeutic strategies Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.Subcellular proteomics revealed the epithelial-mesenchymal transition phenotype in lung cancer.Ablation of Akt2 induces autophagy through cell cycle arrest, the downregulation of p70S6K, and the deregulation of mitochondria in MDA-MB231 cells.Dissecting the M phase-specific phosphorylation of serine-proline or threonine-proline motifs.Cancer stem cells: a novel paradigm for cancer prevention and treatment.

P2860

Q21198874-B98B2FC0-7ABC-4BE5-8CE9-4E1B9F86889A Q21260390-FC123CD6-DD99-4BED-B854-B438628760C3 Q23910293-F2903F61-C1AE-45F8-B85A-AB4AE201FFAE Q24607479-8D587243-02E3-4A25-A519-DA73AA0DABA6 Q24631438-4DD07144-D4CC-40BF-973F-7C36F40EF223 Q26770489-ED443B2F-E291-4649-B919-BBC99792E311 Q26799375-71656D5F-70FF-41E2-8A1D-9F51F4705BB9 Q26829652-650BB7F3-EAE4-4AD3-8FA9-D887C0DE5BD4 Q26852215-B9971882-E513-44FD-885A-A133D3F9535D Q26865957-45D2A512-4B62-4EF8-9CFD-D0FF5F159AA6 Q27027963-5F36F70C-82DE-4BF6-89C6-D6168220265B Q28078891-B970271B-51BF-4D7E-B724-8337A96E847E Q28395771-5B77B36B-42BA-4748-A9FD-7526027C6423 Q28397537-D8A8B672-2706-4477-8E94-B7C2AC7EF277 Q28534403-7FFBB068-820B-48CC-90B5-05EBAFF244CA Q28550200-4B0E8F9B-03BE-45C1-9575-9EB1A397C084 Q28551465-8B3B419B-2AE7-4DB8-B966-98EAD9B102BC Q30437740-F6946584-E33E-48A8-AC0E-6DA96024146C Q30443711-7CC2051A-2D5E-48E2-9E76-47BCB906D1AA Q30481231-F2693006-4998-477A-ACE3-DEDF486B09BD Q32884571-1CEDB429-6C10-420B-9C49-3BF89ADD001D Q33401450-6B0C9B9E-E746-4ECA-9137-2020B4AE1D6B Q33402525-D5565425-651F-4948-BD77-AEA3EBB24473 Q33422258-FA4C02FF-8BE5-4D58-9D64-68C1FFB08564 Q33493174-19005F53-DC94-432C-8EEA-215609584A53 Q33564264-3C3B76AF-6B3C-46A9-903B-CB0A2EE42CDF Q33570393-A0845059-5EC5-4095-8DD5-6D02F52DC278 Q33604979-0E5206EE-55AD-4587-AC9B-A0B468B2754A Q33623582-499F2AB1-FBE9-44C2-89E4-6B90CB8D320E Q33632296-B1C7D258-03D9-40FA-80FE-2A21B4D42EB3 Q33646687-4256F69A-171A-4DB6-ACF3-435CDCCE3E9D Q33661710-CA2909BD-1370-4890-8E1A-C165B1D16A82 Q33685652-E763739D-446F-4591-8054-0A48723CF50C Q33717891-BFC093E5-1FE2-4FC5-9AB6-974A555596CC Q33739184-7BA06852-6ABF-4CC2-9BA1-E4B5BBB409AE Q33755862-9E036CC1-73A8-4770-BE9A-D26BA36D72F7 Q33804107-0310EDA3-92BA-498C-B1AD-50A92593571D Q33812880-10992496-602C-45DC-A460-F57C291E24B4 Q33818450-65DB147B-640D-4915-85AF-64D32EBDD965 Q33867131-9209D624-5CAE-4619-BDE2-38E2C33C5461

P2860

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

http://www.wikidata.org/entity/Q36742629

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

@ast

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

@en

type

label

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

@ast

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

@en

prefLabel

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

@ast

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

@en

P1433

Q36742629-4441ACC2-B64C-4FBF-80D6-440519F1E092

P1476

Q36742629-0DAE8A60-6B80-4887-B2E7-A29D94DE0666

P2093

Q36742629-053C173A-C328-4AFA-B4C8-6FFE467B1B87

Q36742629-1A771EA2-3B3C-4995-BCEF-5BB97425311F

Q36742629-24B7C864-4528-49C5-850C-C5122D75F647

Q36742629-326308C3-8C16-4805-82DA-9A3D1F3F3189

P2860

Q36742629-028D808B-F5B5-4DBC-9591-5E186E708738

Q36742629-051F89E1-14A2-4860-A366-BA6A8EF3A39F

Q36742629-0692B89A-9A37-43C4-9FB7-01AAA43C1C5B

Q36742629-06DCBFD7-8FEB-40D5-917E-0C97C3EF5B58

Q36742629-071946EC-431D-42DC-9A53-5DA8A3975FF5

Q36742629-07CE5CC1-F1AF-4A97-ABC0-E9340439E5BC

Q36742629-08BDCE06-53CA-4B30-A4DF-312B3FDC069B

Q36742629-0976B4FA-96F7-41CC-9AF4-B33E36182E52

Q36742629-098A5E1A-A457-4330-A358-4096E7435B22

Q36742629-0A348E23-04DF-435C-B325-C199558B25BF

P304

Q36742629-2C68CE05-8DE3-4A93-9C98-5620EA4C7290

P31

Q36742629-5DD3A9A4-A9CB-4215-BCD1-7712FDCA2885

P356

Q36742629-32CB1533-2A58-44EB-8812-8D5099238A92

P433

Q36742629-5B5CF3ED-C70F-4CA2-920B-187AF705ED15

P478

Q36742629-85F4FCB3-896F-4F28-96C5-1D74DEB233D4

P577

Q36742629-5C07F40A-EEB1-4C5A-AB9E-E03E9CA6255D

P5875

Q36742629-56DBD834-059F-433E-9215-9508C02AC2A3

P698

Q36742629-B2D5062D-AEF6-4ACD-9E33-2B3CF603A644

P932

Q36742629-F859431B-2210-4BFC-A41E-BA09CFEE9E5C

P356

J.DRUP.2007.11.003

P1433

Drug Resistance Updates

P1476

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

@en

P2093

Gideon M Blumenthal

http://www.w3.org/2001/XMLSchema#string

Jaclyn LoPiccolo

http://www.w3.org/2001/XMLSchema#string

Phillip A Dennis

http://www.w3.org/2001/XMLSchema#string

Wendy B Bernstein

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms

Activation of protein kinase B beta and gamma isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison with protein kinase B alpha

Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA

Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma

Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs

Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.

Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts.

P304

32-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.DRUP.2007.11.003

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2007-12-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5682243

http://www.w3.org/2001/XMLSchema#string

P698

18166498

http://www.w3.org/2001/XMLSchema#string

P932

2442829

http://www.w3.org/2001/XMLSchema#string